SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

  

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 26, 2012 (June 25, 2012)

 

 

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)  

 

Delaware		000-1357459		52-2007292
(State or other jurisdiction of incorporation or organization)		(Commission File No.)		(IRS Employee Identification No.)

 

 

9700 Great Seneca Highway, Rockville, Maryland 20850

(Address of Principal Executive Offices)

 

(301) 366-4841

(Issuer Telephone number)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01.

Other Events.

 

On June 25, 2012, Neuralstem, Inc. (“Company”) announced that the first patients were dosed in the Phase Ib portion of the Company’s ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD). A copy of the press release is attached to this report as Exhibit 99.01.

 

Item 9.01

Financial Statement and Exhibits.

 

Exhibit Number		Description
99.01		Press Release Dated June 25, 2012

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

NEURALSTEM, INC
By:		/s/ I. Richard Garr
		I. Richard Garr
		Chief Executive Officer

 

Dated: June 26, 2012